Loading market dashboard
Penumbra, Inc.
PENHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.
Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone.
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, for each share of Penumbra that they own. KSF is seeki.
Penumbra, Inc. (NYSE: PEN - Get Free Report) Director Harpreet Grewal sold 100 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
PEN's expanding thrombectomy portfolio and global push fuel growth, but FX headwinds and macro risks may pressure near-term profitability.
Congress Asset Management Co. cut its position in shares of Penumbra, Inc. (NYSE: PEN) by 10.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 382,350 shares of the company's stock after selling 46,822 shares during the period. Congress
Penumbra, Inc. (NYSE: PEN - Get Free Report) has received an average recommendation of "Hold" from the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Fourteen analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers
Lombard Medical (OTCMKTS:EVARF - Get Free Report) and Penumbra (NYSE: PEN - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings. Earnings and Valuation This table compares Lombard Medical and
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
Bamco Inc. NY lessened its holdings in Penumbra, Inc. (NYSE: PEN) by 22.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,500 shares of the company's stock after selling 4,000 shares during the quarter. Bamco Inc. NY's
Blair William and Co. IL cut its holdings in Penumbra, Inc. (NYSE: PEN) by 23.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,108 shares of the company's stock after selling 2,456 shares during the quarter. Blair William and Co. IL's holdings
